Gabapentin Extended Release Tablets in Healthy Subjects Under Fed Conditions: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study.

Authors

Sudershan Kumar, Arshad Khuroo, Sanjay Jagannath Gurule, Sachin Mehra, Hari Krishan Tiwari, Y Zala, Venkata Rama Rao Kamala, Madhu Kandukuri, Shruti Dharmadhikari, Prashant Devkare, Chintan Khandhedia

Published in

Drugs in R&D. Jul 01, 2026. Epub Jul 01, 2026.

Abstract

Gabapentin is effective for treating post-herpetic neuralgia and neuropathic pain by stabilizing nerve activity through blocking calcium channels and reducing neurotransmitter release. Gabapentin is available in immediate-release (IR) and extended-release (ER) formulations. A comparative bioavailability study was conducted between Gabapentin ER 600 mg tablets once-daily (OD) (Gabantin^® GRS) [Test (T)] (manufactured by Sun Pharmaceuticals Industries Limited), and Gabapentin Tablets 600 mg OD (Gralise^®) [Reference (R)] (distributed by Almatica Pharma LLC) in healthy human male adults under fed conditions.
In this open-label, balanced, randomized, crossover study each subject received a 600 mg single dose of either T or R in Period 1, followed by crossover treatment in Period 2, with a washout period of 12 days in-between. Pharmacokinetic parameters, including C_max, AUC_0-t, and AUC_0₋∞, were assessed. Safety was monitored through treatment-emergent adverse events (AEs).
All 24 enrolled subjects completed the study. The test formulation demonstrated comparable pharmacokinetic profile to the reference product, meeting the criteria for bioequivalence within acceptable limits (0.80-1.25). The percentage ratio for T vs R product was 0.9171 (90% confidence interval [CI] 0.826-1.0183) for AUC_0-t, 0.9191 (90%CI 0.8279-1.0203) for AUC_0-∞ and 0.9135 (90%CI 0.8324-1.0026) for C_max. Plasma concentration-time profiles were similar. One AE of fever was reported after administration of T; no serious adverse event was reported.
Gabantin^® GRS 600 Tablet ER OD of Sun Pharma had a similar pharmacokinetic profile and was bioequivalent to Gralise^® in healthy subjects under fed conditions with good safety and tolerability profiles.

PMID:
42387089
Bibliographic data and abstract were imported from PubMed on 02 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.